[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ibs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ibs":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100501926","phase-3-ebastine-versus-mebeverine-in-ibs-patients-100501926",false,"NCT05815602","Ebastine Versus Mebeverine in IBS Patients","Multicenter Randomized Controlled Clinical Trial Comparing Ebastine and Mebeverine as Treatment of Irritable Bowel Syndrome","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Patients fulfilling the Rome IV criteria for non-constipated IBS (IBS-C subtypes will be excluded)\n3. No organic cause that can explain the presenting symptoms (exclusion of coeliac disease (blood), lactose intolerance (breath test), inflammatory bowel disease and giardiasis (stool)\n4. Patients with lactose intolerance can be included if no improvement on lactose free diet during 6 weeks\n5. Age 18-65\n\nExclusion Criteria:\n\n1. History of coeliac disease, food allergy, giardiasis, inflammatory bowel disease, infectious gastroenteritis, motility disorder, serious liver kidney cardiac or pulmonary disease, known cardiac rhythm disorders, insuline-dependent diabetes, psychiatric diseases\n2. Pregnancy, breast feeding\n3. Medication: the use of antidepressants or antipsychotics, anti-allergic medication or drugs affecting gastrointestinal motility \u002F visceral sensitivity (anti-cholinergics, antispasmodics, 5-HT3 antagonists, 5-HT4 agonists, loperamide, codeine, laxatives, analgesics: only paracetamol is allowed as analgetic, other analgesics are forbidden.), CYP3A4-inducing and inhibiting drugs. Potent inhibitors of CYP3A4 include clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal and grapefruit. Inducers of CYP3A4 include phenobarbital, phenytoin, rifampicin, St. John's Wort and glucocorticoids.\n4. Symptoms started following abdominal surgery\n5. IBS constipation dominant (IBS-C)\n6. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the SmPC of the respective medicinal products","ALL","18 Years","65 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome\n\nTrial rationale\n\n1. To perform a randomized superiority trial comparing the clinical efficacy of ebastine and mebeverine\n2. To evaluate the impact of treatment with ebastine compared to mebeverine on quality of life and quality-adjusted life years\n\nPrimary objective To provide further evidence of the superiority of histamine 1 receptor antagonism as novel treatment for patients with non-constipated IBS, as compared to mebeverine, one of the spasmolytics currently used as first line treatment of IBS.\n\nSecondary objective(s) To provide evidence that the histamine 1 receptor antagonist ebastine is more effective in reducing abdominal pain compared to the commonly used antispasmodic mebeverine",[27,28],"IBS - Irritable Bowel Syndrome","IBS",[30,31,28,32],"ebastine","duspatalin","Irritable Bowel Syndrome","RECRUITING","2026-03-19",{"date":36,"type":37},"2026-03-23","ACTUAL",{"date":39,"type":37},"2023-03-30",{"date":41,"type":21},"2028-01-01",{"name":43,"class":44},"Guy Boeckxstaens","OTHER",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100202481","measuring-nerve-activity-in-small-human-intestinal-biopsies-in-ibs-irritable-bowel-syndrome-100202481","NCT01912313","Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)","Inclusion Criteria:\n\n* IBS patients (based on ROME III Criteria)\n* Healthy subjects\n\nExclusion Criteria:\n\n\\- All subjects with not IBS related complaints",true,"99 Years",{"count":55,"type":21},99999999,[57],"NA","Rectal biopsies from IBS patients or healthy subjects will be taken.\n\nBiopsies will be used for:\n\n1. the isolation of submucosal plexus to perform: 1.1 live nerve recordings and Calcium imaging; 1.2 immunohistochemistry; 1.3 mRNA (Messenger ribonucleic acids) isolation and real time PCR (Polymerase chain reaction);\n2. culturing biopsies\n\nOn the basis of these observations, the general aim of the study is to move a significant step forward in the current knowledge on human ENS (enteric nervous system) in IBS by establishing a live imaging method to record enteric nerves activity in small intestinal biopsies from humans. This development is unique in its kind as not other research groups have reported successful live recordings with calcium imaging in this preparation.\n\nIn particular, the investigators aim:\n\n1. to develop and validate the technique to measure activity in human enteric nerves in the submucous plexus isolated from rectal biopsies from healthy subjects and IBS patients;\n2. to characterize this nerve activity in healthy subjects and IBS patients using both calcium imaging to evaluate the effect of different neuromodulators, immunohistochemistry and rtPCR to determine receptor expression levels and identify neurons and glial cells in the submucous ganglia;\n3. to investigate whether the biopsies of IBS patients secrete more modulators\u002Fcytokines compared to healthy subjects and their potential to activate neurons.\n4. to evaluate the influence of different food constituents (cow\"s milk, wheat, yeast, gluten and soy) on the local reaction of the rectal mucosa and evaluate mast cell activation\u002Fdegranulation in biopsies of IBS patients compared to healthy subjects.\n5. To evaluate the amount of inflammatory mediators\u002Fmetabolites in urine samples of IBS patients and healthy volunteers by the use of metabolic profiling",[28,60],"Healthy",[62,63],"IBS patients","healthy subjects",{"date":65,"type":37},"2026-03-20",{"date":67,"type":4},"2013-08",{"date":69,"type":21},"2026-12",{"name":71,"class":44},"KU Leuven",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100625751","phase-4-effect-of-multispecies-probiotic-supplementation-on-the-efficacy-of-rifaximin--therapy-in-patients-with-small-intestinal-bacterial-overgrowth-sibo-a-randomized-placebo-controlled-trial-100625751","NCT07426705","Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","Effect of Enterococcus Faecium and Bacillus Subtilis-Containing Multispecies Probiotic Supplementation on the Therapeutic Efficacy of Rifaximin α in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Prospective, Randomized, Placebo-controlled Trial","SIBO-Probiotic","Inclusion Criteria:\n\n* Age ≥18 years.\n* Meets Rome IV criteria for irritable bowel syndrome.\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Lack of cooperation with investigators.\n* Age \\>75 years.\n* Need for modification of gastrointestinal treatment during the study.\n* Use of antibiotics within 4 weeks before screening.\n* Use of probiotics within 7 days before screening.\n* Endoscopic examination within 6 weeks before screening or during the study without investigator approval.\n* History of abdominal surgery.\n* Crohn's disease, ulcerative colitis, microscopic colitis, celiac disease, cystic fibrosis, chronic pancreatitis, liver cirrhosis, or end-stage renal disease.\n* Low FODMAP diet within 4 weeks before screening.\n* Pregnancy or breastfeeding.\n* Lactulose intolerance.","75 Years",{"count":83,"type":21},100,[85],"PHASE4","Small intestinal bacterial overgrowth (SIBO) is a common condition associated with gastrointestinal symptoms such as bloating, abdominal pain, diarrhea, and constipation, particularly in patients with irritable bowel syndrome. Antibiotic therapy with rifaximin is commonly used, but relapse rates remain high.\n\nThis randomized, placebo-controlled clinical trial aims to evaluate whether supplementation with a multispecies probiotic containing Enterococcus faecium and Bacillus subtilis improves the effectiveness of rifaximin therapy in adult patients with SIBO.\n\nParticipants will be randomly assigned to receive either rifaximin plus the probiotic or rifaximin plus placebo. Clinical assessments will include hydrogen breath testing and evaluation of gastrointestinal symptoms using standardized questionnaires at baseline and during follow-up visits.\n\nThe study is being conducted at a single academic medical center in Poland and is sponsored by Państwowy Instytut Medyczny MSWiA. The probiotic and rifaximin are provided by Urgo.\n\nThe results of this study may help determine whether probiotic supplementation can improve treatment outcomes and reduce recurrence of SIBO.",[88,28],"Small Intestinal Bacterial Overgrowth Syndrome (SIBO)",[90,28,91],"SIBO","probiotic","NOT_YET_RECRUITING","2026-02-16",{"date":95,"type":37},"2026-02-23",{"date":97,"type":21},"2026-02-15",{"date":99,"type":21},"2027-07-15",{"name":101,"class":102},"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","OTHER_GOV",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":72},"100241474","visceral-sensitivity-in-ibd-irritable-bowel-disease-and-ibs-irritable-bowel-syndrome-100241474","NCT02421705","Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)","Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors","Inclusion Criteria:\n\nFor group 1: IBS\n\n1. Irritable Bowel Syndrome (IBS) (ROME III criteria)\n2. No obvious organic explanation for the IBS symptoms\n3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nGroup 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nGroup 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)\n\n1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)\n2. remission is confirmed by at least one sigmoidoscopy\n3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\n   Only for group 3a:\n4. Rome III criteria for IBS\n\nGroup 4: Healthy controls No abdominal (pain) complaints.\n\nGroup 5: active Crohn's disease\n\n1\\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nGroup 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)\n\n1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)\n2. remission is confirmed by at least one sigmoidoscopy\n3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nExclusion Criteria:\n\nFor all groups:\n\n1. co-morbidity: severe kidney- and\u002For liver disease or thyroid abnormalities and impaired clotting\n2. Abdominal chirurgy (except for an uncomplicated appendectomy)",{"count":55,"type":21},[57],"Aim:\n\nMore insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.",[28,114,115,116,117,118],"Ulcerative Colitis, Active","Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms)","Healthy Controls","Crohn's Disease, Active","Crohn's Disease, Remission (6a: With IBS Symptoms, 6b: Without IBS Symptoms)","2023-02-07",{"date":121,"type":37},"2023-02-08",{"date":123,"type":4},"2010-02",{"date":125,"type":21},"2099-01",{"name":71,"class":44}]